Renaissance Technologies’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-96,042
| Closed | -$22.1K | – | 3951 |
|
|
2024
Q4 | $22.1K | Sell |
96,042
-393
| -0.4% | -$472 | ﹤0.01% | 3478 |
|
|
2024
Q3 | $207K | Sell |
96,435
-21,000
| -18% | -$75.4K | ﹤0.01% | 3116 |
|
|
2024
Q2 | $606K | Sell |
117,435
-2,400
| -2% | -$12.6K | ﹤0.01% | 2607 |
|
|
2024
Q1 | $641K | Buy |
119,835
+61,200
| +104% | +$423K | ﹤0.01% | 2765 |
|
|
2023
Q4 | $457K | Buy |
58,635
+9,400
| +19% | +$32.2K | ﹤0.01% | 2821 |
|
|
2023
Q3 | $194K | Buy |
49,235
+3,100
| +7% | +$11.6K | ﹤0.01% | 3102 |
|
|
2023
Q2 | $145K | Buy |
46,135
+300
| +0.7% | +$964 | ﹤0.01% | 3377 |
|
|
2023
Q1 | $122K | Sell |
45,835
-1,400
| -3% | -$5.43K | ﹤0.01% | 3426 |
|
|
2022
Q4 | $170K | Buy |
47,235
+3,500
| +8% | +$15.2K | ﹤0.01% | 3474 |
|
|
2022
Q3 | $282K | Buy |
43,735
+834
| +2% | +$6.78K | ﹤0.01% | 3239 |
|
|
2022
Q2 | $413K | Sell |
42,901
-38,995
| -48% | -$365K | ﹤0.01% | 3267 |
|
|
2022
Q1 | $975K | Buy |
+81,896
| New | +$1.46M | ﹤0.01% | 2739 |
|
|
2021
Q1 | – | Sell |
-8,670
| Closed | -$941K | – | 3792 |
|
|
2020
Q4 | $941K | Buy |
+8,670
| New | +$791K | ﹤0.01% | 2527 |
|
|
2020
Q3 | – | Sell |
-5,830
| Closed | -$621K | – | 3764 |
|
|
2020
Q2 | $621K | Buy |
+5,830
| New | +$523K | ﹤0.01% | 2788 |
|
|
2020
Q1 | – | Sell |
-12,909
| Closed | -$892K | – | 3884 |
|
|
2019
Q4 | $892K | Sell |
12,909
-15,751
| -55% | -$955K | ﹤0.01% | 2685 |
|
|
2019
Q3 | $2.98M | Sell |
28,660
-1,080
| -4% | -$102K | ﹤0.01% | 2065 |
|
|
2019
Q2 | $2.75M | Buy |
29,740
+7,690
| +35% | +$535K | ﹤0.01% | 2164 |
|
|
2019
Q1 | $2.02M | Buy |
22,050
+9,580
| +77% | +$667K | ﹤0.01% | 2303 |
|
|
2018
Q4 | $695K | Buy |
12,470
+9,640
| +341% | +$732K | ﹤0.01% | 2734 |
|
|
2018
Q3 | $337K | Sell |
2,830
-13,660
| -83% | -$1.58M | ﹤0.01% | 2979 |
|
|
2018
Q2 | $1.68M | Buy |
+16,490
| New | +$2.04M | ﹤0.01% | 2357 |
|
|
2017
Q4 | – | Sell |
-7,220
| Closed | -$1.06M | – | 3530 |
|
|
2017
Q3 | $1.06M | Buy |
7,220
+4,520
| +167% | +$850K | ﹤0.01% | 2551 |
|
|
2017
Q2 | $434K | Buy |
+2,700
| New | +$424K | ﹤0.01% | 2801 |
|
Other funds holding SYRS
BBA
1CM
XT
Renaissance Technologies's SYRS Position: Q1 2025 in Review
Renaissance Technologies sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 96,042 shares — an estimated $22.1K sold.
Renaissance Technologies first reported a position in SYRS in Q2 2017 and held it in 23 quarters. The position peaked at $2.98M in Q3 2019. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Renaissance Technologies reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Renaissance Technologies sold 96,042 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $22.1K.
- Renaissance Technologies first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 23 quarters.
- Renaissance Technologies's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.98M in Q3 2019.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.